140 related articles for article (PubMed ID: 14597871)
1. Capecitabine monotherapy and in combination with immunotherapy in the treatment of metastatic renal cell carcinoma.
Wenzel C; Locker GJ; Bartsch R; Pluschnig U; Mader R; Hussian D; Kramer G; Marberger M; Lintner C; Rauchenwald M; Zielinski CC; Steger GG
Anticancer Drugs; 2003 Nov; 14(10):779-84. PubMed ID: 14597871
[TBL] [Abstract][Full Text] [Related]
2. Capecitabine in the treatment of metastatic renal cell carcinoma failing immunotherapy.
Wenzel C; Locker GJ; Schmidinger M; Mader R; Kramer G; Marberger M; Rauchenwald M; Zielinski CC; Steger GG
Am J Kidney Dis; 2002 Jan; 39(1):48-54. PubMed ID: 11774101
[TBL] [Abstract][Full Text] [Related]
3. Capecitabine as third-line treatment in patients with metastatic renal cell carcinoma after failing immunotherapy.
Petrioli R; Paolelli L; Francini E; Marsili S; Pascucci A; Sciandivasci A; de Rubertis G; Barbanti G; Manganelli A; Salvestrini F; Francini G
Anticancer Drugs; 2007 Aug; 18(7):817-20. PubMed ID: 17581304
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma.
Pagliaro LC; Perez CA; Tu SM; Daliani DD
Urol Oncol; 2006; 24(6):487-91. PubMed ID: 17138128
[TBL] [Abstract][Full Text] [Related]
5. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
Olencki T; Peereboom D; Wood L; Budd GT; Novick A; Finke J; McLain D; Elson P; Bukowski RM
J Cancer Res Clin Oncol; 2001 May; 127(5):319-24. PubMed ID: 11355147
[TBL] [Abstract][Full Text] [Related]
6. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study.
Padrik P; Leppik K; Arak A
Urol Oncol; 2004; 22(5):387-92. PubMed ID: 15464918
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine in the treatment of metastatic renal cell carcinoma.
Oevermann K; Buer J; Hoffmann R; Franzke A; Schrader A; Patzelt T; Kirchner H; Atzpodien J
Br J Cancer; 2000 Sep; 83(5):583-7. PubMed ID: 10944596
[TBL] [Abstract][Full Text] [Related]
8. A phase-II study of combination of pegylated interferon alfa-2a and capecitabine in locally advanced or metastatic renal cell cancer.
Sunela KL; Koskinen S; Kellokumpu-Lehtinen PL
Cancer Chemother Pharmacol; 2010 May; 66(1):59-67. PubMed ID: 19771431
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial.
Walter B; Schrettenbrunner I; Vogelhuber M; Grassinger J; Bross K; Wilke J; Suedhoff T; Berand A; Wieland WF; Rogenhofer S; Andreesen R; Reichle A
Med Oncol; 2012 Jun; 29(2):799-805. PubMed ID: 21607771
[TBL] [Abstract][Full Text] [Related]
10. A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Amato RJ; Khan M
Cancer Chemother Pharmacol; 2008 May; 61(6):1069-73. PubMed ID: 17701037
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of capecitabine and rHu-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy, and moderate toxicity.
Segota E; Mekhail T; Olencki T; Hutson TE; Dreicer R; Wacker B; Osterwalder B; Elson P; Zhou M; Bukowski RM
Urol Oncol; 2007; 25(1):46-52. PubMed ID: 17208138
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of capecitabine and weekly docetaxel in metastatic renal cell carcinoma.
Marur S; Eliason J; Heilbrun LK; Dickow B; Smith DW; Baranowski K; Alhasan S; Vaishampayan U
Urology; 2008 Oct; 72(4):898-902. PubMed ID: 18692873
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer.
Kusama M; Nomizu T; Aogi K; Yoshimoto M; Horikoshi N; Tabei T; Noguchi S; Miura S; Yoshimura N; Kimura M; Toyama K; Shin E
Breast Cancer; 2010 Oct; 17(4):233-40. PubMed ID: 19633909
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine in hormone-resistant metastatic prostatic carcinoma - a phase II trial.
Morant R; Bernhard J; Dietrich D; Gillessen S; Bonomo M; Borner M; Bauer J; Cerny T; Rochlitz C; Wernli M; Gschwend A; Hanselmann S; Hering F; Schmid HP
Br J Cancer; 2004 Apr; 90(7):1312-7. PubMed ID: 15054447
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
16. Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer.
Huang H; Jiang Z; Wang T; Zhang S; Bian L; Cao Y; Wu S; Song S
Anticancer Drugs; 2012 Aug; 23(7):718-23. PubMed ID: 22739713
[TBL] [Abstract][Full Text] [Related]
17. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of capecitabine in combination with interferon alpha in patients with metastatic renal cancer: toxicity and pharmacokinetics.
Chang DZ; Olencki T; Budd GT; Peereboom D; Ganapathi R; Osterwalder B; Bukowski R
Cancer Chemother Pharmacol; 2001 Dec; 48(6):493-8. PubMed ID: 11800031
[TBL] [Abstract][Full Text] [Related]
19. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
Rini BI; Weinberg V; Small EJ
Cancer; 2005 Feb; 103(3):553-8. PubMed ID: 15612026
[TBL] [Abstract][Full Text] [Related]
20. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study.
Allen MJ; Vaughan M; Webb A; Johnston S; Savage P; Eisen T; Bate S; Moore J; Ahern R; Gore ME
Br J Cancer; 2000 Oct; 83(8):980-5. PubMed ID: 10993642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
